Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 299

1.

Erratum. Baseline Characteristics of the Vitamin D and Type 2 Diabetes (D2d) Study: A Contemporary Prediabetes Cohort That Will Inform Diabetes Prevention Efforts. Diabetes Care 2018;41:1590-1599.

LeBlanc ES, Pratley RE, Dawson-Hughes B, Staten MA, Sheehan PR, Lewis MR, Peters A, Kim SH, Chatterjee R, Aroda VR, Chadha C, Neff LM, Brodsky IG, Rosen C, Desouza CV, Foreyt JP, Hsia DS, Johnson KC, Raskin P, Kashyap SR, O'Neil P, Phillips LS, Rasouli N, Liao EP, Robbins DC, Pittas AG; D2d Research Group.

Diabetes Care. 2019 Sep 23. pii: dc19er12. doi: 10.2337/dc19-er12. [Epub ahead of print] No abstract available.

PMID:
31548246
2.

Vitamin D Supplementation and Prevention of Type 2 Diabetes.

Pittas AG, Dawson-Hughes B, Sheehan P, Ware JH, Knowler WC, Aroda VR, Brodsky I, Ceglia L, Chadha C, Chatterjee R, Desouza C, Dolor R, Foreyt J, Fuss P, Ghazi A, Hsia DS, Johnson KC, Kashyap SR, Kim S, LeBlanc ES, Lewis MR, Liao E, Neff LM, Nelson J, O'Neil P, Park J, Peters A, Phillips LS, Pratley R, Raskin P, Rasouli N, Robbins D, Rosen C, Vickery EM, Staten M; D2d Research Group.

N Engl J Med. 2019 Aug 8;381(6):520-530. doi: 10.1056/NEJMoa1900906. Epub 2019 Jun 7.

PMID:
31173679
3.

The Association of Coronary Artery Calcification With Subsequent Incidence of Cardiovascular Disease in Type 1 Diabetes: The DCCT/EDIC Trials.

Budoff M, Backlund JC, Bluemke DA, Polak J, Bebu I, Schade D, Strowig S, Raskin P, Lachin JM; DCCT/EDIC Research Group.

JACC Cardiovasc Imaging. 2019 Jul;12(7 Pt 2):1341-1349. doi: 10.1016/j.jcmg.2019.01.014. Epub 2019 Mar 13.

PMID:
30878435
4.

Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease.

Chertow GM, Appel GB, Block GA, Chin MP, Coyne DW, Goldsberry A, Kalantar-Zadeh K, Meyer CJ, Molitch ME, Pergola PE, Raskin P, Silva AL, Spinowitz B, Sprague SM, Rossing P.

J Diabetes Complications. 2018 Dec;32(12):1113-1117. doi: 10.1016/j.jdiacomp.2018.09.005. Epub 2018 Sep 13.

5.

Baseline Characteristics of the Vitamin D and Type 2 Diabetes (D2d) Study: A Contemporary Prediabetes Cohort That Will Inform Diabetes Prevention Efforts.

LeBlanc ES, Pratley RE, Dawson-Hughes B, Staten MA, Sheehan PR, Lewis MR, Peters A, Kim SH, Chatterjee R, Aroda VR, Chadha C, Neff LM, Brodsky IG, Rosen C, Desouza CV, Foreyt JP, Hsia DS, Johnson KC, Raskin P, Kashyap SR, O'Neil P, Phillips LS, Rasouli N, Liao EP, Robbins DC, Pittas AG; D2d Research Group.

Diabetes Care. 2018 Aug;41(8):1590-1599. doi: 10.2337/dc18-0240. Epub 2018 Jun 25. Erratum in: Diabetes Care. 2019 Sep 23;:.

6.

The effect of basal-bolus therapy varies with baseline 1,5-anhydroglucitol level in people with Type 2 diabetes: a post hoc analysis.

Heller S, Bowering K, Raskin P, Liebl A, Buchholtz K, Gorst-Rasmussen A, Pieber TR.

Diabet Med. 2018 May 26. doi: 10.1111/dme.13693. [Epub ahead of print]

7.

"She's woke": The paradoxical effects of the 2016 election on an individual client.

Raskin PM.

J Clin Psychol. 2018 May;74(5):743-749. doi: 10.1002/jclp.22604. Epub 2018 Mar 12.

PMID:
29528497
8.

Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study).

Aroda VR, Bailey TS, Cariou B, Kumar S, Leiter LA, Raskin P, Zacho J, Andersen TH, Philis-Tsimikas A.

Diabetes Obes Metab. 2016 Jul;18(7):663-70. doi: 10.1111/dom.12661. Epub 2016 May 2. Erratum in: Diabetes Obes Metab. 2016 Sep;18(9):952.

9.

Bromocriptine-QR therapy for the management of type 2 diabetes mellitus: developmental basis and therapeutic profile summary.

Raskin P, Cincotta AH.

Expert Rev Endocrinol Metab. 2016 Mar;11(2):113-148. doi: 10.1586/17446651.2016.1131119.

PMID:
30058874
10.

AMG 151 (ARRY-403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes.

Katz L, Manamley N, Snyder WJ, Dodds M, Agafonova N, Sierra-Johnson J, Cruz M, Kaur P, Mudaliar S, Raskin P, Kewalramani R, Pellacani A.

Diabetes Obes Metab. 2016 Feb;18(2):191-5. doi: 10.1111/dom.12586. Epub 2015 Dec 14.

PMID:
26434934
11.

Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.

Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR.

J Clin Invest. 2015 Aug 3;125(8):3285-96. doi: 10.1172/JCI81722. Epub 2015 Jul 20.

13.

Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy Using an NSAID for Other Pain Conditions: A Double-Blind Crossover Study.

Raskin P, Huffman C, Yurkewicz L, Pauer L, Scavone JM, Yang R, Parsons B.

Clin J Pain. 2016 Mar;32(3):203-10. doi: 10.1097/AJP.0000000000000254.

PMID:
25968451
14.

Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes.

Mann KV, Raskin P.

Diabetes Metab Syndr Obes. 2014 Jun 24;7:229-39. doi: 10.2147/DMSO.S35331. eCollection 2014. Review.

15.

Consensus Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology insulin pump management task force.

Grunberger G, Abelseth JM, Bailey TS, Bode BW, Handelsman Y, Hellman R, Jovanovič L, Lane WS, Raskin P, Tamborlane WV, Rothermel C.

Endocr Pract. 2014 May;20(5):463-89. doi: 10.4158/EP14145.PS. No abstract available.

PMID:
24816754
16.

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.

Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR; T1DAL Study Team.

Lancet Diabetes Endocrinol. 2013 Dec;1(4):284-94. doi: 10.1016/S2213-8587(13)70111-6. Epub 2013 Sep 23.

17.

Intensive therapy in newly diagnosed type 2 diabetes: results of a 6-year randomized trial.

Harrison LB, Adams-Huet B, Li X, Raskin P, Lingvay I.

J Investig Med. 2014 Apr;62(4):676-86. doi: 10.2310/JIM.0000000000000068.

18.

Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment.

Orban T, Bundy B, Becker DJ, Dimeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Peakman M, Raskin P, Russell WE, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS; Type 1 Diabetes TrialNet Abatacept Study Group.

Diabetes Care. 2014 Apr;37(4):1069-75. doi: 10.2337/dc13-0604. Epub 2013 Dec 2.

19.

A novel glucose-insulin infusion maintains perioperative glycaemic control through multiple transitions of care.

Renthal N, Roe ED, Adams-Huet B, Raskin P.

J Perioper Pract. 2013 Oct;23(10):222-7.

PMID:
24279037
20.

B-lymphocyte depletion with rituximab and β-cell function: two-year results.

Pescovitz MD, Greenbaum CJ, Bundy B, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, Moran A, Raskin P, Rodriguez H, Schatz DA, Wherrett DK, Wilson DM, Krischer JP, Skyler JS; Type 1 Diabetes TrialNet Anti-CD20 Study Group.

Diabetes Care. 2014 Feb;37(2):453-9. doi: 10.2337/dc13-0626. Epub 2013 Sep 11.

21.

Pregabalin in patients with inadequately treated painful diabetic peripheral neuropathy: a randomized withdrawal trial.

Raskin P, Huffman C, Toth C, Asmus MJ, Messig M, Sanchez RJ, Pauer L.

Clin J Pain. 2014 May;30(5):379-90. doi: 10.1097/AJP.0b013e31829ea1a1.

PMID:
23887339
22.

Haptoglobin genotype and the rate of renal function decline in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study.

Orchard TJ, Sun W, Cleary PA, Genuth SM, Lachin JM, McGee P, Paterson AD, Raskin P, Anbinder Y, Levy AP; DCCT/EDIC Research Group.

Diabetes. 2013 Sep;62(9):3218-23. doi: 10.2337/db13-0256. Epub 2013 Jun 12.

23.

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.

Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS; Type 1 Diabetes TrialNet Canakinumab Study Group, Pickersgill L, de Koning E, Ziegler AG, Böehm B, Badenhoop K, Schloot N, Bak JF, Pozzilli P, Mauricio D, Donath MY, Castaño L, Wägner A, Lervang HH, Perrild H, Mandrup-Poulsen T; AIDA Study Group.

Lancet. 2013 Jun 1;381(9881):1905-15. doi: 10.1016/S0140-6736(13)60023-9. Epub 2013 Apr 5.

24.

Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.

Raskin P.

Diabetes Metab Res Rev. 2013 Jul;29(5):347-56. doi: 10.1002/dmrr.2403. Review.

PMID:
23463735
25.

Response to Comment on: Harrison et al. β-cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care 2012;35:1406-1412.

Harrison LB, Raskin P, Lingvay I.

Diabetes Care. 2013 Jan;36(1):e17. doi: 10.2337/dc12-1659. No abstract available.

26.

Managing inpatient hyperglycemia in a resource-constrained county hospital: the Parkland Memorial Hospital experience.

Roe ED, Raskin P.

Hosp Pract (1995). 2012 Aug;40(3):116-25. doi: 10.3810/hp.2012.08.995.

PMID:
23086100
27.

Iatrogenic hyperinsulinemia in type 1 diabetes: its effect on atherogenic risk markers.

Wang MY, Yu X, Lee Y, McCorkle SK, Clark GO, Strowig S, Unger RH, Raskin P.

J Diabetes Complications. 2013 Jan-Feb;27(1):70-4. doi: 10.1016/j.jdiacomp.2012.08.008. Epub 2012 Oct 15.

PMID:
23079124
28.

β-cell function preservation after 3.5 years of intensive diabetes therapy.

Harrison LB, Adams-Huet B, Raskin P, Lingvay I.

Diabetes Care. 2012 Jul;35(7):1406-12. doi: 10.2337/dc11-2170.

29.

Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: a randomized trial.

Raskin P, Heller S, Honka M, Chang PC, Boss AH, Richardson PC, Amin N.

Diabetes Obes Metab. 2012 Feb;14(2):163-73. doi: 10.1111/j.1463-1326.2011.01500.x. Epub 2011 Nov 3.

PMID:
21951325
30.

Comparison of a novel insulin bolus-patch with pen/syringe injection to deliver mealtime insulin for efficacy, preference, and quality of life in adults with diabetes: a randomized, crossover, multicenter study.

Bohannon N, Bergenstal R, Cuddihy R, Kruger D, List S, Massaro E, Molitch M, Raskin P, Remtema H, Strowig S, Whitehouse F, Brunelle RL, Dreon D, Tan M.

Diabetes Technol Ther. 2011 Oct;13(10):1031-7. doi: 10.1089/dia.2011.0047. Epub 2011 Jul 6.

31.

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.

Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Raskin P, Rodriguez H, Russell WE, Schatz D, Wherrett D, Wilson DM, Krischer JP, Skyler JS; Type 1 Diabetes TrialNet Abatacept Study Group.

Lancet. 2011 Jul 30;378(9789):412-9. doi: 10.1016/S0140-6736(11)60886-6. Epub 2011 Jun 28.

32.

Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.

Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Herold KC, Marks JB, Monzavi R, Moran A, Orban T, Palmer JP, Raskin P, Rodriguez H, Schatz D, Wilson DM, Krischer JP, Skyler JS; Type 1 Diabetes TrialNet GAD Study Group.

Lancet. 2011 Jul 23;378(9788):319-27. doi: 10.1016/S0140-6736(11)60895-7. Epub 2011 Jun 27.

33.

Bardoxolone methyl and kidney function in CKD with type 2 diabetes.

Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB, Krauth M, Ruiz S, Audhya P, Christ-Schmidt H, Wittes J, Warnock DG; BEAM Study Investigators.

N Engl J Med. 2011 Jul 28;365(4):327-36. doi: 10.1056/NEJMoa1105351. Epub 2011 Jun 24.

34.

A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure.

Davidson MB, Raskin P, Tanenberg RJ, Vlajnic A, Hollander P.

Endocr Pract. 2011 May-Jun;17(3):395-403. doi: 10.4158/EP10323.OR.

PMID:
21324825
35.

Updated review: improved glycemic control with repaglinide-metformin in fixed combination for patients with type 2 diabetes.

Richard JW 3rd, Raskin P.

Clin Med Insights Endocrinol Diabetes. 2011;4:29-37. doi: 10.4137/CMED.S5094. Epub 2011 Jun 7.

36.

The impact of continuous subcutaneous insulin infusion and multiple daily injections of insulin on glucose variability in older adults with type 2 diabetes.

Johnson SL, McEwen LN, Newton CA, Martin CL, Raskin P, Halter JB, Herman WH.

J Diabetes Complications. 2011 Jul-Aug;25(4):211-5. doi: 10.1016/j.jdiacomp.2010.09.005. Epub 2010 Nov 9.

PMID:
21062674
37.

Glycaemic control with liraglutide: the phase 3 trial programme.

Raskin P, Mora PF.

Int J Clin Pract Suppl. 2010 Oct;(167):21-7. doi: 10.1111/j.1742-1241.2010.02496.x. Review.

PMID:
20887301
39.

Comparison of once-weekly with twice-daily exenatide in the treatment of type 2 diabetes (DURATION-1 trial).

Raskin P, Mohan A.

Expert Opin Pharmacother. 2010 Sep;11(13):2269-71. doi: 10.1517/14656566.2010.497142.

PMID:
20536293
40.

Emerging treatments for the prevention of type 1 diabetes.

Raskin P, Mohan A.

Expert Opin Emerg Drugs. 2010 Jun;15(2):225-36. doi: 10.1517/14728211003694631. Review.

PMID:
20384544
41.

Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.

Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, Lachin JM, Skyler JS; Type 1 Diabetes TrialNet Anti-CD20 Study Group.

N Engl J Med. 2009 Nov 26;361(22):2143-52. doi: 10.1056/NEJMoa0904452.

42.

Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.

Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD.

J Am Soc Nephrol. 2009 Dec;20(12):2641-50. doi: 10.1681/ASN.2009070737. Epub 2009 Nov 19.

43.

Review of clinical trials: update on oral insulin spray formulation.

Pozzilli P, Raskin P, Parkin CG.

Diabetes Obes Metab. 2010 Feb;12(2):91-6. doi: 10.1111/j.1463-1326.2009.01127.x. Epub 2009 Nov 2. Review.

PMID:
19889002
44.

Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better?

Lingvay I, Legendre JL, Kaloyanova PF, Zhang S, Adams-Huet B, Raskin P.

Diabetes Care. 2009 Oct;32(10):1789-95. doi: 10.2337/dc09-0653. Epub 2009 Jul 10.

45.

Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes.

Raskin P, Gylvin T, Weng W, Chaykin L.

Diabetes Metab Res Rev. 2009 Sep;25(6):542-8. doi: 10.1002/dmrr.989.

PMID:
19565569
46.

Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control.

Raskin P, Lewin A, Reinhardt R, Lyness W; Repaglinide/Metformin Fixed-Dose Combination Study Group.

Diabetes Obes Metab. 2009 Oct;11(10):947-52. doi: 10.1111/j.1463-1326.2009.01069.x. Epub 2009 Jun 16.

PMID:
19531054
47.

Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.

Blonde L, Merilainen M, Karwe V, Raskin P; TITRATE Study Group.

Diabetes Obes Metab. 2009 Jun;11(6):623-31. doi: 10.1111/j.1463-1326.2009.01060.x.

PMID:
19515182
48.

Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet.

Raskin P, Lewin A, Reinhardt R, Lyness W; Repaglinide/Metformin Fixed-Dose Combination Study Group.

Diabetes Obes Metab. 2009 Sep;11(9):865-73. doi: 10.1111/j.1463-1326.2009.01062.x. Epub 2009 May 19.

PMID:
19476470
49.

Vascular effects of rapid-acting insulin analogs in the diabetic patient: a review.

Fordan S, Raskin P.

Vasc Health Risk Manag. 2009;5(1):225-31. Epub 2009 Apr 8. Review.

50.

The fatty hearts of patients with diabetes.

Lingvay I, Raskin P, Szczepaniak LS.

Nat Rev Cardiol. 2009 Apr;6(4):268-9. doi: 10.1038/nrcardio.2009.30.

PMID:
19352328

Supplemental Content

Loading ...
Support Center